帕妥珠单抗
医学
曲妥珠单抗
乳腺癌
多西紫杉醇
内科学
肿瘤科
养生
新辅助治疗
卡铂
腋窝
化疗
癌症
顺铂
作者
Coralia Bueno,Isabel Echavarría,Sara López‐Tarruella,Marta Roche-Molina,Marı́a del Monte-Millán,Tatiana Massarrah,Yolanda Jerez,Francisco Ayala de la Peña,José Á. García-Sáenz,Fernando Moreno,Álvaro Rodríguez-Lescure,Diego Malón,Ana Isabel Ballesteros García,Mercedes Marín‐Aguilera,Patricia Galván,Fara Brasó‐Maristany,Adrienne G. Waks,Sara M. Tolaney,Elizabeth A. Mittendorf,Ana Vivancos
出处
期刊:JAMA Oncology
[American Medical Association]
日期:2023-04-27
卷期号:9 (6): 841-841
被引量:20
标识
DOI:10.1001/jamaoncol.2023.0187
摘要
Biomarkers to guide the use of pertuzumab in the treatment of early-stage ERBB2 (formerly HER2)-positive breast cancer beyond simple ERBB2 status are needed.
科研通智能强力驱动
Strongly Powered by AbleSci AI